Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06271577 · ClinicalTrials.gov registry record · NA
Smartphone Twelve-Lead ECG Utility In ST-Elevation Myocardial Infarction II
A NA study of Heart Failure and Cardiovascular Diseases, sponsored by AliveCor.
- Recruiting
- Registry status
- NA
- Development phase
- 1,000
- Enrollment target
- 2
- Study locations
NCT06271577: Recruiting NA study of Heart Failure and Cardiovascular Diseases, sponsored by AliveCor.
NCT06271577 is a NA study of Heart Failure and Cardiovascular Diseases that is actively recruiting participants, run by AliveCor. The registered enrollment target is 1,000 participants, below the 2,047-participant average among 397 other Heart Failure trials with a reported enrollment target (51% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06271577, a NA study of Heart Failure and Cardiovascular Diseases, is actively recruiting participants, sponsored by AliveCor.
- RECRUITING
- Registry status
- NA
- Development phase
- 1,000 participants
- Enrollment target
- 2
- Study locations
Study Summary
AliveCor (www.alivecor.com) has developed several electrocardiogram (ECG) devices that interface with iOS and Android smartphones and tablets via various Kardia apps. The current Kardia family of devices can measure single lead and six limb-lead ECGs, depending on the device. KardiaMobile, KardiaMobile 6L, and KardiaMobile Card have FDA clearance for ECG rhythm recording. A modified single-lead Kardia smartphone 12-lead ECG was previously validated in the multicenter ST LEUIS study for the diagnosis of ST-Segment Elevation Myocardial Infarction (STEMI) and Non-ST-Elevation Myocardial Infarction (NSTEMI). Recently, AliveCor developed a new device: AliveCor (AC) 12-lead (12L) ECG System to record simultaneously 4 leads of ECG and then generate complete 12-lead ECGs. A previous protocol at the University of Oklahoma involved 200 subjects with early prototypes of the AC 12L device with the specific aim to validate that it accurately generated 12-lead ECGs as compared to simultaneously acquired FDA-cleared 12-lead ECGs. The prototype version of the AliveCor 12L ECG System simultaneously measured four channels of ECG (leads I, II, V2, V4), calculated the remaining limb leads as is standard for 12-lead ECGs (Leads III, aVR, aVL, aVF) and synthesized the remaining 4 precordial ECG leads (V1, V3, V5, V6). This protocol will serve to validate the production version of the system against standard 12-Lead ECGs for the diagnosis of STEMI and NSTEMI in patients admitted to the Emergency Department or directly to the Cardiac Cath Lab for the evaluation of chest pain. It is anticipated that the waveforms for each of the 12 leads from the AC 12L ECG System will be highly correlated with the corresponding leads from the comparator commercially available 12-lead ECG devices used at participating sites. The purpose of this study is to clinically validate that the four-channel AC 12L ECG device can enable the diagnosis of STEMI and NSTEMI in a non-inferior manner to existing 12-lead EC
Conditions Studied
Interventions
- DEVICE AliveCor 12-lead ECG
Study Locations (2)
Minnesota
- Mayo Clinic - Rochester
Utah
- Intermountain Health - Murray
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2024-03-12 |
| Est. Completion | 2024-12 |
| Phase | NA |
What NCT06271577 shows while recruiting
NCT06271577 is an interventional study that assigns participants to a tested intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus, below the 2,047-participant average among 397 other Heart Failure trials with a reported enrollment target (51% lower).
The record links to 8 conditions, with Heart Failure appearing as the primary indexed condition, and to 1 intervention - of which AliveCor 12-lead ECG is the first listed.
NCT06271577 reports a single indexed study location in Minnesota, Utah.
Frequently Asked Questions
What is clinical trial NCT06271577 about?
NCT06271577 is a clinical study titled "Smartphone Twelve-Lead ECG Utility In ST-Elevation Myocardial Infarction II". AliveCor (www.alivecor.com) has developed several electrocardiogram (ECG) devices that interface with iOS and Android smartphones and tablets via various Kardia apps. The current Kardia family of devices can measure single lead and six limb-lead ECGs, depending on the device. KardiaMobile, KardiaMob...
What is the current status of trial NCT06271577?
This trial is currently recruiting. It is a NA study. The enrollment target is 1,000 participants. The study started on 2024-03-12. Estimated completion is 2024-12.
What conditions does trial NCT06271577 study?
This clinical trial studies the following conditions: Heart Failure, Cardiovascular Diseases, Heart Diseases, Myocardial Infarction, Vascular Diseases.
What interventions are being tested in trial NCT06271577?
The interventions under investigation include: AliveCor 12-lead ECG (DEVICE).
Who is sponsoring clinical trial NCT06271577?
This trial is sponsored by AliveCor, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06271577 being conducted?
This trial has 2 study locations across Minnesota, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06271577's enrollment target sits among peer trials
1,000 67th of 397 higher than 325 of 397 other Heart Failure trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Heart Failure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Early Feasibility Study of the NORM™ System in Heart Failure Patients (FUTURE-HFII)
RECRUITING · NA
-
Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure
RECRUITING · NA
-
iCardia4HF: Multi-component mHealth Intervention for Patients With Heart Failure
RECRUITING · NA
-
Optimizing Heart Failure Therapies Among Patients With Limited Access in Denver
RECRUITING · NA
-
Hemodynamic Monitoring to Prevent Adverse Events foLlowing cardiOgenic Shock Trial
RECRUITING · NA
-
Effect of a Quality Improvement Initiative to Address Social Determinants of Health on Rehospitalization Rates in Patients With Heart Failure
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
- NCT01553214 · 1,000 participants · Phase 4
Improving White Blood Cell Collection From Healthy Donors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI